Innogenetics partners with PamGene to develop its new generation multi parameter diagnostic platform
Gent (Belgium) and Den Bosch (the Netherlands) - Innogenetics and PamGene International today announced an agreement whereby Innogenetics gains access to PamGene's microarray technology platform for the development of its next generation nucleic acid and protein-based tests. By combining Innogenetics' expertise in developing and marketing specialty diagnostics and PamGene's advanced technology platform, multi parameter assays will be developed and updated rapidly, thus reducing their time-to-market.
The exclusive license, secured by Innogenetics on PamGene's technology, covers the PamStation(TM) 12 dedicated instrumentation in those areas where Innogenetics is currently active (infectious diseases, genetic testing and neurodegeneration) with an optional extension for applications in the field of oncology. The agreement includes an upfront payment, staged development milestone fees as new tests reach the market, and royalties on sales.
Upon thorough evaluation of different technology alternatives, Innogenetics selected PamGene's advanced microarray technology as its platform combined with its PamStation(TM) 12 instrumentation. This approach allows Innogenetics to develop tests that can assess up to 400 different parameters in one sample run (a tenfold increase compared to Innogenetics' current LiPA and LIA technology).
The first set of assays based on the new platform is expected to reach the market in 2006.
According to Tim Kievits, Chief Executive Officer of PamGene, "This partnership with Innogenetics validates our technology in the clinical setting and is a perfect match that links the speed and user-friendliness of our advanced multi parameter approach with Innogenetics' proven ability to develop high-quality specialty diagnostics. The diagnostic market is especially keen on using state-of-the-art tests that can identify which patients are more suited to a particular therapy, and indicate how well a treatment is working. Such tailored medicine will open new avenues to optimize healthcare."
Philippe Archinard, CEO of Innogenetics, added, "Our new collaboration with PamGene will ensure the expansion of our activities into high-performance multi parameter diagnostics to maintain our leadership position in highly innovative specialty diagnostics. These new tests will be progressively developed by Innogenetics using the PamGene platform, and will offer unique and attractive features to serve the needs of clinical laboratories, such as real-time monitoring, quantitation, automation, user-friendliness, and rapid updating."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
